Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Background: The pharmacokinetics and appropriate dose regimens of favipiravir are unknown in hospitalized influenza patients; such data are also needed to determine dosage selection for favipiravir trials in COVID-19. Methods: In this dose-escalating study, favipiravir pharmacokinetics and tolerabil...

Full description

Bibliographic Details
Main Authors: Yeming Wang, Wu Zhong, Alex Salam, Joel Tarning, Qingyuan Zhan, Jian-an Huang, Heng Weng, Changqing Bai, Yanhong Ren, Koichi Yamada, Dayan Wang, Qiang Guo, Qiongqiong Fang, Sakurai Tsutomu, Xiaohui Zou, Haibo Li, Annelies Gillesen, Lyndsey Castle, Cheng Chen, Hongyan Li, Jing Zhen, Binghuai Lu, Jun Duan, Liping Guo, Jinfang Jiang, Ruiyuan Cao, Guohui Fan, Jintong Li, Frederick G. Hayden, Chen Wang, Peter Horby, Bin Cao
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:EBioMedicine
Subjects:
Favipiravir
Pharmacokinetics
Concentration
Influenza
COVID-19
Critical illness
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420305016

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420305016

Similar Items